You are here

vaccines

Initial Ph II 2b Results of Elios' Personalized Cancer Vaccine for the Treatment of Melanoma Look Promising

Initial Ph II 2b Results of Elios' Personalized Cancer Vaccine for the Treatment of Melanoma Look Promising

CP Wire

Elios Therapeutics

clinical trials

Flag link:

Sanofi ups the ante in vaccines—big-time—with new €350M plant

Sanofi ups the ante in vaccines—big-time—with new €350M plant

Fierce Pharma

drug manufacturing

Flag link:

Don't sweat Prevnar's problems, Pfizer R&D chief says. New vaccines are on their way

Don't sweat Prevnar's problems, Pfizer R&D chief says. New vaccines are on their way

Fierce Pharma

Flag link:

In salvage effort, Sellas cherry picks some positive mid-stage cancer vaccine data

In salvage effort, Sellas cherry picks some positive mid-stage cancer vaccine data

Endpoints

Galena Biopharma

cancer vaccines

Flag link:

World's first Lassa vaccine, developed by Themis, nears human testing: CEO

World's first Lassa vaccine, developed by Themis, nears human testing: CEO

Fierce Pharma

Flag link:

Sanofi and NIH Start Trials for H7N9 Flu Vaccine

Sanofi and NIH Start Trials for H7N9 Flu Vaccine

Xtalks

clinical trials

Flag link:

GlaxoSmithKline scores retail deal with CVS, spreading Shingrix to thousands of pharmacies

GlaxoSmithKline scores retail deal with CVS, spreading Shingrix to thousands of pharmacies

Fierce Pharma

Flag link:

After a rough season, FDA chief Gottlieb says 'holy grail' flu shot is years off

After a rough season, FDA chief Gottlieb says 'holy grail' flu shot is years off

Fierce Pharma

universal flu vaccine

Flag link:

Needle-free flu vaccine will be back in clinics next flu season

Needle-free flu vaccine will be back in clinics next flu season

Drug Delivery Business News

needle free delivery

Flag link:

Sanofi again denies Dengvaxia refund request as Philippine officials prep lawsuit

Sanofi again denies Dengvaxia refund request as Philippine officials prep lawsuit

Fierce Pharma

Flag link:

With weeks left in flu season, the FDA is already working on next year’s vaccine

With weeks left in flu season, the FDA is already working on next year’s vaccine

Drug Delivery Business News

drug development

Flag link:

GlaxoSmithKline tops its peers with $7.16B in 2017 vaccine sales

GlaxoSmithKline tops its peers with $7.16B in 2017 vaccine sales

Fierce Pharma

Flag link:

As raging flu epidemic spreads, Sanofi Pasteur targets more effective cell-based universal vaccine

As raging flu epidemic spreads, Sanofi Pasteur targets more effective cell-based universal vaccine

Fierce Pharma

universal flu vaccine

Flag link:

Bavarian Nordic unveils positive smallpox vaccine data

Bavarian Nordic unveils positive smallpox vaccine data

Biopharma Dive

Bavarian Nordic

Flag link:

Gardasil grows, Zostavax struggles as Merck posts $6.5B in 2017 vaccine sales

Gardasil grows, Zostavax struggles as Merck posts $6.5B in 2017 vaccine sales

Fierce Pharma

Flag link:

Sanofi rejects Philippine plea for refund on used vaccines

Sanofi rejects Philippine plea for refund on used vaccines

Yahoo/AP

Flag link:

3 Headwinds in Q4 Earnings Results That Make Merck a Mediocre Stock

3 Headwinds in Q4 Earnings Results That Make Merck a Mediocre Stock

Motley Fool

cardiovascular disease

Flag link:

Shingrix Could Be a Long-Term Growth Driver for GlaxoSmithKline

Shingrix Could Be a Long-Term Growth Driver for GlaxoSmithKline

Market Realist

Flag link:

Watch These February Biotech Catalysts

Watch These February Biotech Catalysts

Seeking Alpha

Puma Biotechnology

Flag link:

How Sanofi's setback could lead to better dengue vaccines

How Sanofi's setback could lead to better dengue vaccines

Reuters

Takeda Pharmaceuticals

Flag link:

Pages